

# Migraine screening in oncohematologic patients with ID Migraine™ questionnaire



## Aim

To assess ID Migraine™ questionnaire sensitivity and specificity in oncohematologic patients

## Methods

Adult oncohematologic patients referred to a neurologist

Early post-transplant period (up to day 100) and ICU excluded

268 participants

*(Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Pavlov University, Saint Petersburg, Russia)*

Assessment by a blinded neurologist

Pretest criteria

## Results

Headache: n = 58 (21.6%)  
Migraine without aura: 11.6%  
Infrequent episodic tension-type headache: 4.9%  
Post-dural puncture headache: 5.9%

39 patients screened with ID Migraine™

91.3% (95% CI, 72.0% to 98.9%)

62.5% (95% CI, 35.4% to 84.8%)

In oncohematologic patients, ID migraine™ showed **high sensitivity** and **low specificity**.

